

Statement of Advice

**infliximab (Remicade®) 100 mg powder for concentrate for solution
for infusion (No: 739/11)**

Merck Sharp & Dohme Ltd

9 September 2011

ADVICE: in the absence of a submission from the holder of the marketing authorisation

infliximab (Remicade®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of moderately active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Following NHS Quality Improvement Scotland's endorsement of the National Institute for Health and Clinical Excellence (NICE) multiple technology appraisal guidance No 187, infliximab is recommended as a treatment option in **severe** active Crohn's disease.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman,
Scottish Medicines Consortium**